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Abstract
Background: Bone marrow stromal cells (BMSCs) are being used to treat a variety of conditions. For many
applications a supply of cryopreserved products that can be used for acute therapy is needed. The establishment
of a bank of BMSC products from healthy third party donors is described.
Methods: The recruitment of healthy subjects willing to donate marrow for BMSC production and the Good
Manufacturing Practices (GMP) used for assessing potential donors, collecting marrow, culturing BMSCs and BMSC
cryopreservation are described.
Results: Seventeen subjects were enrolled in our marrow collection protocol for BMSC production. Six of the 17
subjects were found to be ineligible during the donor screening process and one became ill and their donation
was cancelled. Approximately 12 ml of marrow was aspirated from one posterior iliac crest of 10 donors; one
donor donated twice. The BMSCs were initially cultured in T-75 flasks and then expanded for three passages in
multilayer cell factories. The final BMSC product was packaged into units of 100 × 10
6 viable cells, cryopreserved
and stored in a vapor phase liquid nitrogen tank under continuous monitoring. BMSC products meeting all lot
release criteria were obtained from 8 of the 11 marrow collections. The rate of growth of the primary cultures was
similar for all products except those generated from the two oldest donors. One lot did not meet the criteria for
final release; its CD34 antigen expression was greater than the cut off set at 5%. The mean number of BMSC units
obtained from each donor was 17 and ranged from 3 to 40.
Conclusions: The production of large numbers of BMSCs from bone marrow aspirates of healthy donors is
feasible, but is limited by the high number of donors that did not meet eligibility criteria and products that did
not meet lot release criteria.
Background
Bone marrow-derived stromal cells (BMSCs) are adult
multipotent cells that can be isolated from bone marrow
[1,2]. For their multitude of actions they represent a
very attractive tool in cellular therapies; osteogenesis
imperfecta [3,4], acute and chronic graft versus host dis-
ease (GVHD) [5-11], inflammatory bowel disease [12],
ischemic heart disease [13], non-healing ulcers [14],
ischemic stroke [15], multiple sclerosis [16], amyo-
trophic lateral sclerosis [16,17], Parkinson’s disease [18],
a n ds p i n a lc o r di n j u r y[ 1 9 ] .T h e s ea r eo n l yaf e w
examples of their application in phase I, II and III clini-
cal trials.
Traditionally, BMSCs are derived from marrow aspi-
rates or marrow tissue associated with surgical bone
specimens or bone biopsies, but the percentage of mar-
row cells which are BMSCs is very low; between 0.01-
0.001%. For in vivo use, BMSCs must be expanded to
reach adequate numbers for therapeutic doses. For this
reason cell processing facilities have established pro-
cesses for the large scale production of BMSCs for auto-
logous use when long-term BMSC engraftment and
differentiation may be required and the use of HLA-
matched BMSCs is needed [20-22]. However, when
long-term survival of BMSCs is not necessary, the use of
BMSCs without regard for HLA-matching has been
shown to be effective. The effectiveness of third party
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host immune and inflammatory response by cytokines
and growth factors released by BMSCs. For these appli-
cations banks of third party human BMSCs have been
created where BMSCs are isolated, expanded ex vivo
over several weeks, cryopreserved and finally thawed
and administered to patients determined eligible for spe-
cific treatments [5,6,10].
In 2008 the NIH Bone Marrow Stromal Cell Trans-
plantation Center (BMSC TC) was established. The aim
of the center was to create the infrastructure to manu-
facture clinical grade human BMSCs and to facilitate
the use of ex vivo expanded BMSCs for the treatment of
patients with a variety of human diseases and disorders
within the Clinical Center. In this paper we report the
manufacturing process we have optimized and validated
to produce “clinical grade” BMSCs in support of the
BMSC TC activities. The processes used to screen
donors, collect marrow, and to produce and cryopre-
serve BMSCs are described as well as the results of the
first 11 full scale BMSC production runs in our GMP
facility.
Methods
Donor eligibility and donor screening process
All donors were required to meet Food and Drug
Administration (FDA) and AABB (formally the Ameri-
can Association of Blood Banks) criteria for cellular
therapy donors. A protocol for the donation of marrow
for BMSC production was created, posted on the NIH
website and registered in clinicaltrials.gov with the iden-
tification number NCT01071577. Potential volunteers
made the initial contact with the Department of Trans-
fusion Medicine (DTM, NIH) by phone or email and
the protocol procedures and risks were explained.
Demographic information, an abbreviated questionnaire
for determination of risk factors for transmissible infec-
tions including recent travel outside of the USA or
Canada and an abbreviated medical history were
obtained. If no factors were identified that would make
him/her ineligible, they were then invited to make a fol-
low-up appointment in the Donor Center for a complete
donor eligibility evaluation. At this point a NIH healthy
volunteer consent was obtained and a unique NIH med-
ical record number (MRN) assigned and legal identifica-
tion verified to insure correct patient identity and age
since the donor’s age must be greater than or equal to
18 years. In a private setting a thorough explanation of
the protocol including risks was completed, time was
allowed for donor questions, and then informed consent
obtained. Three forms, AABB donor education materi-
als, medical deferral list, and foreign travel information
sheet (a list of medications that cause deferral and a list
of the countries in Europe and the United Kingdom
where travel or residency can result in a permanent
deferral from donating due to variant Creutzfeldt-Jakob
disease (vCJD) risk) were reviewed. An FDA approved
standardized screening questionnaire for cellular therapy
products was administered verbally by trained DTM
staff and answers were recorded on paper. This ques-
tionnaire documents an abbreviated medical history and
screens for risk factors that identify a donor’s potential
for exposure to HIV, hepatitis, and other viral infections
as well as exposure to malaria, vCJD and other diseases.
This paper became part of the official record that is
kept in a secure folder in a locked room.
Donor testing
A brief physical exam was performed; blood samples
were collected and tested for markers of transfusion
transmitted diseases (TTD), complete blood counts
(CBC), coagulation assays, HLA type, ABO blood group
and pregnancy where appropriate. Donors were tested
for anti-HIV-1/2, hepatitis B virus surface antigen (HBs
Ag), anti-hepatitis B virus core antigen (anti-HBC), anti-
hepatitis C virus (anti-HCV), RPR-Treponema pallidum
(syphilis), anti-HTLV-1, anti-HTLV-2, cytomegalovirus
IgG, IgM antibody (anti-CMV), anti-T. Cruzi (Chagas),
HIV-1/HCV/HBV nucleic acid testing (NAT) and West
N i l eV i r u sN A T .D o n o r sw e r ea l s ot e s t e df o rC B Cw i t h
differential white cell count, prothrombin time (PT),
partial thromboplastin time (PTT) and HLA- A, B, C
and DR/DQ. With the exception of the RPR, the TTD
tests were sent to an outside FDA approved laboratory
for donor screening assays. The donor must have a pla-
telet count > 150 × 10
9/L, absolute neutrophil count >
1.0 × 10
9/L and hemoglobin > 11.5 g/dL for African or
African American women, > 12.0 g/dL for all other
women and 12.5 g/dL for all men and the PT and PTT
must be within normal limits. The results of the TTD,
CBC, PT, PTT and pregnancy assays were used to deter-
mine donor eligibility while the results of ABO blood
g r o u pa n dH L At y p ew e r eu s e df o ri d e n t i t yt e s t i n go f
the product.
If the potential donor met the eligibility criteria, the
marrow aspiration was scheduled. This was done within
30 days of the pre-screening visit according to AABB
and FDA standards.
Bone marrow collection
On the day of marrow aspiration, the donors first
reported to the Blood Donor Center and were registered
into our center’s Blood Bank Computer System (BBCS,
Blood Bank Computer Systems Inc, Auburn, Washing-
ton), a password protected data management system
that assigns each donor a unique donor identification
number and tracts the results of donor screening via a
Self Reporting Questionnaire (SRQ) as well as physical
examination, ABO grouping and transfusion transmitted
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viated physical exam was repeated and another blood
sample was collected for TTD testing and ABO group-
ing as previously reported.
The donor was then taken to a hospital procedure
room. First, the risks of bone marrow aspiration were
reviewed and a surgical consent was signed by each
donor. As required by the Joint Commission on Accred-
itation of Healthcare Organizations (JCAHO), a “time
out” was taken to verify donor identity and donor
understanding of the procedure to be performed. Bone
marrow aspirates were collected according to the stan-
dard procedure in use at the NIH Clinical Center; the
protocol allows for bilateral collection, but to date uni-
lateral aspirates only have been collected.
A 1 mL aliquot of bone marrow at each collection was
evaluated by a hematopathology medical technologist in
the Department of Laboratory Medicine for the presence
of bone spicules as a measurement of aspirate quality; a
marrow smear and peripheral blood smear is reviewed
as well for normal trilineage hematopoiesis. A limited
volume of marrow was aspirated (max 12 mL) to avoid
excessive dilution with peripheral blood, and collected
in multiple 3 mL Bone Marrow Prep Syringes (Phar-
macy Department, CC, NIH) containing DMEM,
heparin and gentamicin. Syringes were properly labeled
and transported at room temperature to the CPS
laboratory.
Marrow processing and BMSC production
Receipt of marrow by the cell processing laboratory
The marrow aspirate was received by trained cell pro-
cessing laboratory staff. At the time of receipt each syr-
inge was inspected and its appearance, identifiers and
time of receipt was documented. The samples were pro-
cessed immediately, but the laboratory’s procedures
allow samples to be stored at 2-8°C for a maximum of 4
h prior to processing.
Overview of processing
The BMSCs were initially cultured in T-75 flasks. They
were then expanded for three passages in multilayer cell
factories. At the completion of the processing the
BMSCs from the final harvest were packaged into units
of 100 million viable cells, cryopreserved and stored in
the vapor phase of a liquid nitrogen storage tank.
Marrow aspirate receipt and evaluation
After receipt, the aspirates were pooled into a 50 mL
conical tube (BD Falcon, BD Biosciences, Bedford, MA)
and total volume estimated and diluted up to 3.5 times
by adding Bone Marrow Stromal Cell Culture Media
(BMSC CM) which consisted of: alpha MEM (Lonza,
Walkersville, MD) supplemented with 20% lot-selected
US origin Defined Fetal Bovine Serum (FBS) (Hyclone
Laboratories, Inc., Logan, UT) and gentamicin sulfate
(10 mcg/mL) (Gentamicin, injection, UPS, AAPP Phar-
maceuticals, LCC, Schaumburg, IL). A single cell sus-
pension was prepared; cells were passed through an 18
ga spinal needle (18 ga, 3.5 in., Monoject, Covidien,
Mansfield, MA) twice and then through a 20 ga spinal
needle (BD Spinal Needle, BD Medical, Franklin Lakes,
NJ) twice and resuspended in 20 to 30 mL with BMSC
CM.
A 1 mL aliquot of solution was removed for cell
counts (Celldyne 3700, Abbott Laboratories Inc., Abbot
Park, IL), and analysis by flow cytometry for CD3 and
CD34 content and viability using 7AAD (BD FACS-
Canto, BD Biosciences, San Jose, CA) (Table 1). An in-
process control was set at this point and the aspirate
was discarded if the total nucleated cell (TNC) count
was < 20 × 10
6. Colony Formation Efficiency (CFE) was
performed as previously described [23] as a quality mea-
sure of the starting material. The CFE and CD34+ cell
counts were obtained for retrospective analysis, but
were not used to qualify the starting material.
Initial growth of BMSCs
The BMSCs were initially grown in T-75 flasks (75 cm
2
flask, canted neck, nonpyrogenic, sterile polystyrene,
Corning Incorporated, Corning, NY). The flasks were
seeded at a cell density of 2 to 3 × 10
5 cells per cm
2 of
surface area and a final volume of 20 mL BMSC CM.
The flasks were incubated at 37°C in 5% CO2 and 90 ±
5% humidity. Thirty percent of the flasks were used to
assess colony formation and confluence periodically dur-
ing the culture by evaluating 40% of the surface of the
bottom of the flasks.
On day 1 of culture, 24 h after plating the cells, super-
natants containing non-adherent cells were removed
through complete media exchange and the flasks re-
incubated at 37°C in 5% CO2 and 90 ± 5% humidity.
Thereafter, complete media exchange was performed
every 3 days. On day 7 the flasks assigned for colony
Table 1 BMSC lot release criteria
Test Method Criteria
CD73 Flow cytometry ≥80% reactive cells
CD90 Flow cytometry ≥80% reactive cells
CD105 Flow cytometry ≥80% reactive cells
CD146 Flow cytometry ≥60% reactive cells
CD34 Flow cytometry ≤5% reactive cells
CD45 Flow cytometry ≤5% reactive cells
CD14 Flow cytometry ≤5% reactive cells
CD11b Flow cytometry ≤5% reactive cells
Viability Trypan blue ≥70%
Sterility Bactec Plus, aerobic and
anaerobic
No growth after 14
days
Mycoplasma PCR Negative
Endotoxin Limulus Amebocyte Lysate (LAL) < 5.0 EU/mL
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microscope and under 25× magnification. If no colonies
were detected, the cultures were discontinued; other-
wise, the cultures were maintained. Beginning on day 10
the number of colonies with more than 50 cells and >
70% confluence and with more than 50 cells and < 70%
confluence was recorded. If more than half the colonies
were > 70% confluent, the cells were harvested. If less
than half the colonies were > 70% confluent, then
BMSC CM media was replaced and the process repeated
the next day. Colony counting and confluence assess-
ment continued daily until the harvest criteria were met
or the culture reached Day 13; the cultures were termi-
nated if the criteria were not met.
Primary culture was harvested by trypsinization. We
used commercially available recombinant trypsin (Try-
PLE Express Invitrogen, CA) to limit the usage of ani-
mal derived reagents. An aliquot of the final harvested
cells was assessed for manual cell counts and viability by
the trypan blue exclusion method and sterility (BD
BACTEC plus + aerobic/F and BD BACTEC plus +
anaerobic/F, Becton Dickenson and Company, Sparks,
MD). The BMSCs were also evaluated by flow cytometry
for the expression of BMSC surface markers according
to the ISCT panel. The culture was discontinued if via-
bility was < 70% or sterility testing was positive. The iso-
lated BMSCs were designated passage 1 cells.
In vitro expansion
Passage 1 BMSCs were seeded in 2-layer cell factories
(Cell Factory, easy fill 2-trays, Nunc A/S, Roskilde, Den-
mark) at a cell density of 2,500-4,000 cells/cm
2.T h e
plating density was based on published data. A maxi-
mum of 4 culture vessels were seeded for each proces-
sing event due to the maximum capacity of the GMP
processing suite dedicated to BMSCs production. To
facilitate the handling of cultures a peristaltic pump
using an adaptor specifically designed was used for
media and cell loading (Fluid transfer tube set, Baxa
Corporation, Englewood, CO). The media levels were
equalized on the two layers and the cell factories were
incubated at 37°C with 5% CO2 and 90 ± 5% humidity.
On day 3 complete media exchange was performed.
Cells were harvested on day 5 or 6 once the culture met
the criteria defined as 70% confluence. Culture was dis-
carded if confluence was < 70% on day 6. Harvest was
performed as for flasks using TryPLE express. If the
volume of the cells recovered was less than or equal to
1200 mL, it was reduced using a floor model centrifuge
(Sorvall RC3, DuPont, Newtown, CT) set at 406 g for 10
mins. If the volume was > 1200 mL a cell washer (Cobe
2991 cell processor, Caridian BCT, Lakewood, CO) was
used. The passage 2 BMSCs were resuspended in 50 mL
of BMSC CM and 0.5 mL was removed for manual cell
counts and viability assessment using trypan blue
staining. The culture at this point was terminated if the
viability was < 70%.
BMSC passage 2 culture
Passage 2 BMSCs were seeded in 10-layer cell factories
(Cell Factory, easy fill 10-trays, Nunc A/S) at a cell den-
sity of 2,500-4,000 cells/cm
2. After measuring the num-
ber of BMSCs harvested, the number of 10-layer cell
factories, each of which has a surface area of 6,300 cm
2,
that could be seeded and the number of cells to place in
each cell factory was calculated. Our protocol permits a
maximum of four 10-layer cell factories to be seeded
with passage 2 cells. Approximately 20 × 10
6 per 10-
layer cell factory in a final volume of 2.5 L BMSC CM
per container was loaded using the automatic system
described above. The media levels were equalized and
cell factories incubated at 37°C with 5% CO2 and 90 ±
5% humidity. On culture day 3, a complete media
exchange was performed, and a volume of 2.5 L fresh
BMSC CM was added. The cell harvest was planned for
day 5 or 6 according to the degree of cell confluence.
The culture was discontinued if cell confluence was <
70% on day 6.
Harvested passage 3 cells were assessed for cell count
and viability. The harvested BMSCs were concentrated
using a cell washer (Cobe 2991 Cell Processor) and
resuspended in 100 mL of BMSC CM.
BMSC passage 3 culture
For passage 3 culture, 10-layer cell factories were
seeded, incubated and monitored as described for pas-
sage 2, however, up to eight 10-layer cell factories were
seeded. The 10-layer cell factories were also harvested
on Day 5 or 6 according to confluence and the same
criteria for selecting the harvest day was used. For this
step HBSS with 5% heat inactivated AB plasma (HIAB)
was used to inactivate the trypsin instead of BMSC CM
to reduce residual level of bovine contaminants.
The final product was concentrated and washed thor-
oughly using a cell washer (Cobe 2991 cell processor).
After loading the cells into the cell processor, they were
washed for 5 cycles with Plasmalyte A (Baxter Health-
care Corporation, Westlake Village, CA) containing 0.5%
HSA (Fexbumin 25% (Human) USP, 25% solution, Bax-
ter Healthcare Corporation). The washed cells were
then resuspended in Plasmalyte A with 4% HSA.
The harvested passage 4 BMSCs were counted manu-
ally and assessed for viability by the trypan blue exclu-
sion method, and for safety with endotoxin, sterility, and
mycoplasma by PCR analysis. Cell surface marker
expression was assessed by flow cytometry. The cells
were discarded if they did not meet lot release criteria
(Table 1). The number of aliquots of 100 × 10
6 viable
BMSCs that could be cryopreserved was calculated and
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malyte A with 4% HSA for each 100 × 10
6 unit of viable
cells.
Cryopreservation and storage
A total of 10 mL of BMSCs at 10 × 10
6 cells per mL
were mixed with 10 mL of freeze mix consisting of 10%
DMSO, 12% Pentastarch and 8% Human Serum Albu-
min (HSA) in plasmalyte A and transferred into custo-
mized 20 mL FEP cryobags (AFC Kryosure VP-20f,
Gaithersburg, MD, USA). The cells were cryopreserved
using a controlled rate freezer (Kryosave, Integra, Planer
plc, Sunbury-on-Thames, UK) and stored in the vapor
phase of a liquid nitrogen tank. Each cryobag with 100
×1 0
6 BMSCs was considered a “unit” of BMSCs. A spe-
cific label was applied according to ISBT standards.
Quality assurance systems
A specific software program for capturing cellular ther-
apy data (StemLab, STEMSOFT Software Inc., Vancou-
ver, British Columbia, Canada) was used in the process
described above. All components used in the manufac-
turing process were taken into account and recorded for
further tracking: equipment, starting cellular material,
ancillary reagents, materials, product inventory, person-
nel and methods.
Regulatory considerations
All marrow was collected and BMSCs produced under a
NHLBI IRB approved protocol and a DTM, CC, NIH
Drug Master File. BMSC products are available for
administration to Clinical Center patients who are
enrolled in NIH intramural program IRB approved
treatment protocols. All patients must also be treated
under an Investigational New Drug (IND) application.
Statistical analysis
The values shown are the mean ± 1 standard deviation
(SD). The correlation coefficients and p-values were cal-
culated by a regression model. The significance between
2 groups was evaluated by student t-test. P <0 . 0 5w a s
considered significant. All the plots and statistical analy-
sis were completed by using Microsoft Excel 2007.
Results
Marrow was collected from 10 healthy donors. In order
to identify these 10 donors a total of 17 donors were
enrolled into the marrow aspiration protocol and were
evaluated at our center. Of these 17 potential donors, 6
were found to be ineligible during the screening process
and one developed an illness immediately prior to the
scheduled donation (Table 2). A 49-year-old male was
i n e l i g i b l eb e c a u s eo fah i s t o r yo fap r o l o n g e ds t a yi na
vCJD risk area, a 31-year-old female because of a low
hemoglobin level and a 52-year-old male because of a
reactive TTD test. A 26-year-old female was ineligible
due to a history of an event that placed her at risk of a
TTD, a 30-year-old woman had an elevated PTT result
and a 25-year-old female had evidence of an acute CMV
infection. A 24-year-old female developed an acute ill-
ness the day of the scheduled donation and was not
allowed to donate. The remaining 10 donors met donor
eligibility criteria and marrow was collected once from 9
donors and twice from one donor, donor 1. These 10
donors ranged in age from 21 to 67 years and 7 were
male (Table 2).
The total volume of aspirated marrow plus media in
the 8 syringes obtained from each donor ranged from
21 to 27 mL. The total number of nucleated cells col-
lected was 345 ± 233 × 10
6 (mean 1 ± SD) and ranged
from 127 × 10
6 to 788 × 10
6; the average proportion of
c e l l se x p r e s s i n gC D 3 4w a s1 . 3 5±0 . 5 6 %a n dr a n g e d
0.45% to 2.26%. Bone marrow spicules were present in
all aspirates except those from donor 4. All marrow
aspirate and peripheral blood smears were within nor-
mal limits.
For all 11 donations, BMSC colonies were detected in
T-75 flasks in the primary culture at day 7. For marrow
aspirates from donors 4 and 15, an insufficient number
of colonies were detected on day 7 to continue on the
culture. For the second marrow aspirate from donor 1,
during the culture of BMSCs in 2-layer factories, post-
donation information became known that made the
donor ineligible and the culture was discarded. The
other 8 donations were successfully cultured through
passage 4 and the cells were harvested (Table 3). The
final yield of BMSCs ranged from 990 × 10
6 to 4760 ×
10
6 resulting in 9 to 40 BMSC units. BMSC products
from 7 of the 8 donations met all lot release criteria
including sterility testing, viability testing, and flow mar-
ker analysis (Table 4). The expression of CD34 antigen
by BMSCs from donor 15, 5.6%, exceeded the lot release
criteria of ≤5%.
In general, TNC and CD34 percentage of marrow cells
from younger donors were higher than those from older
donors (Figure 1, Panel A), however the correlation was
not significant (p = 0.06 between age and TNC; p =
0.23 between CD34 percentage and age). Similarly, abso-
lute number of CD34 positive cells tended to be inver-
sely correlated with age (p = 0.13, Figure 1, Panel B).
Interestingly, among the 11 collections, the TNC and
number of CD34 positive cells collected from the two
oldest donors, 59 and 67 years old, were the lowest, and
their cells failed to meet colony formation criteria at the
end of the primary culture.
We assessed the CFE of the marrow aspirated from
each donor. There was a highly significant inverse corre-
lation between CFE and the age of donors (p = 0.01, R =
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BMSCs harvested from primary culture tended to
decrease when age increased, but the correlation was
not significant (p = 0.07, Figure 2, Panel A). The inverse
correlation between CFE and age was observed in both
female and male donors, and no significance difference
in CFE was observed between males and females (p =
0 . 9 4 ,F i g u r e2 ,P a n e lB ) .S i m i l a r l y ,t h eq u a n t i t yo f
BMSCs in the primary harvest did not differ significantly
between males and females (p = 0.96, Figure 2, Panel C).
Of note, the number of BMSCs from the primary har-
vest increased as the CFE increased (p = 0.05, Figure 2,
Panel D).
Among all the potential predictors for BMSC final
harvest, the quantity of BMSCs in the primary harvest
was the best one. It had a highly significant correlation
with quantity of BMSCs in the final harvest (p = 0.008,
R = 0.84, Figure 3, Panel A). The quantity of BMSCs in
the final harvest decreased as donor age increased (p =
0.15, R = -0.56, Figure 3, Panel B), but was not affected
by the marrow aspirate TNC count (p = 0.46, Figure 3,
Panel C) or CFE (p = 0.42, Figure 3, Panel D). However,
there was an inverse correlation between quantity of
BMSCs in the final harvest and the percentage of CD34
positive cells in the marrow aspirate, although the corre-
lation was not significant (p = 0.11, R = -0.61, Figure 3,
Panel E).
Discussion
We established a mechanism to manufacture and store
BMSC products from healthy subjects. The BMSC bank
was established to support the activity of the NIH Bone
Marrow Stromal Cell Transplantation Center which
involves the treatment of patients at the NIH Clinical
Center who are enrolled in IRB approved treatment pro-
tocols. Our banked cells were produced from bone mar-
row aspirates from healthy subjects, which were plated
without removal of red blood cells and expanded using
progressively larger plastic surfaces up to passage 4.
Although this restriction on passage number limited the
quantity of BMSCs produced, it was chosen based upon
data collected in preclinical studies which showed that
limiting BMSC expansion to less than 40-50 population
doublings minimized growth related senescence. The
banked products we manufactured differ from those
manufactured at some other centers in that we only
produced cells from third party donors rather than both
relatives of patients needing BMSC therapy and third
Table 2 Characteristics of healthy subjects agreeing to donate marrow for BMSC production and the aspirated marrow
Donor Aspirated Marrow
Age (years) Volume* (mL) TNC (10
6) CD34 CD3
Number Gender Race (%) #(10
6)% #
1 35.6 M AA 21 165 2.26 3.73 10.7 17.7
2 22.9 M W 26 266 1.56 4.15 11.7 31.1
3 22.8 F W 27.5 374 1.20 4.48 13.3 49.7
4 67.9 F W 27 127 0.71 0.90 5.19 6.59
5 21.7 M W 25 584 0.66 3.85 7.62 44.5
6† 49.5 M W vCJD risk NA NA NA NA NA
7 23.7 F W 24.8 788 1.71 13.5 6.89 54.3
8† 52.1 M W + TTD test NA NA NA NA NA
9† 31.5 F AA Low Hgb NA NA NA NA NA
10 27.2 M AA 27 681 1.44 1.44 6.81 46.4
11 56.8 M W 26 228 1.4 3.19 9.38 21.4
12† 24.9 F W Sick NA NA NA NA NA
13† 26.6 F AA TTD risk NA NA NA NA NA
1ŧ 36.5 M AA 25.6 153 1.99 3.04 10.4 15.9
14 21.3 M AA 27 271 1.45 3.93 13.5 36.6
15 59.4 M W 25 160 0.45 0.72 8.67 13.9
16 25.2 F W +CMV IgM NA NA NA NA NA
17† 30.8 F A Elev. PTT NA NA NA NA NA
*Volume volume of media plus volume of aspirated marrow
† Ineligible to donate
Ŧ marrow was collected from donor 1 twice
NA not applicable
M male; F female
AA African American; W White
TTD transfusion transmitted disease
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T-75 flasks 2-layer cells factories First culture in 10-layer cell
factories

































W092110086001 1 6 6.5 94.4 3.9 30.9 0.81 3.2 37.3 1.73 3.4 34.9 10.5 10
W092110086002 2 18 30.3 372 4.5 26.4 0.99 3.6 33 2.43 3.9 30.6 12 19
W092110086003 3 9 21 314.3 4.3 27.9 1.28 4 30 1.61 3.3 36 11.6 14
W092110086004 4 0 0.2 NA NA NA NA NA NA NA NA NA NA NA
W092110086005 5 11.5 52.1 456.4 4.8 24.8 1.23 3.9 30.4 4.76 4.9 24.5 13.6 40
W092110086006 7 15 28 372.5 4.5 26.4 0.9 3.5 34.3 2.17 3.8 31.9 11.8 20
W092110086007 10 1.5 25.4 255.4 4 30 1.1 3.8 31.8 1.66 3.4 35.6 11.2 15
W092111086001 11 7.5 3.9 27.9 3.9 30.9 0.15 2.9 49.8 0.99 3 47.2 8.8 9
W092111086002 1 7 3.1 NA NA NA NA NA NA NA NA NA NA NA
W092111086003 14 5.5 12.9 233.2 4.3 28 0.97 3.6 33.3 2.52 3.98 30.2 11.9 23
W092111086004 15 4.5 2.2 NA NA NA NA NA NA NA NA NA NA NA



















































































































2party donors [6,10]. Our bank also does not include the
storage of intermediate products for further manufac-
ture [9,13,24]. These intermediary products are thawed
and further expanded increasing their time in culture
which increases the possibility of producing senescent
cells, and a potentially less active final product com-
pared to BMSCs products made up of younger cells
[9,14,25].
Our established process allowed for the production of
9 to 40 doses of BMSCs from each donor. The currently
approved treatment protocols at our institution involve
the treatment of patients two to three times with a dose
of 1 to 2 × 10
6 cells per kg weight. As a result approxi-
mately 2 to 9 BMSCs products are needed to treat each
patient. Whenever possible each BMSC recipient is
given BMSCs from a single donor or lot, so each lot
could treat 1 to 20 patients. We have, however, elected
to limit the use of each lot to the treatment of 1 to 4
recipients. While all donors meet cell therapy donor cri-
teria and are tested in the same manner as whole blood,
platelet apheresis donors and allogeneic cell therapy
donors, there is a remote, but real possibility that
BMSCs could transmit a pathogen to the recipient. Lim-
iting the number of people treated with each lot limits
the number of recipients exposed to a potential
pathogen.
We found that the CFE of the aspirated marrow and
the quantity of BMSCs in the primary and final harvests
were less in older donors. The results are similar to pre-
vious studies which found that CFE of marrow prepara-
tions was greater in younger subjects [23]. It may be
worthwhile to limit the collection of marrow for the
production for BMSCs to younger donors, but sufficient
data is not yet available to establish an upper age limit.
We also found that the quantity of BMSCs in the final
harvest was most closely related to the quantity obtained
from the primary harvest.
BMSCs produced by our center have several potential
advantages over the use of BMSCs from centralized or
commercial facilities that produce multiple large lots of
BMSCs from a single donor. Our BMSC products are
earlier passage cells. The properties of BMSCs change
with serial passage. Late passage BMSCs are less potent
than early passage BMSCs in several assays. Their prolif-
eration rate is less and their osteogenic and adipogenic
differentiation potential is reduced [26,27]. When
BMSCs are co-cultured with hematopoietic stem and
progenitor cells (HPC), early passage BMSCs maintained
Table 4 Characteristics of the 8 lots of BMSCs Produced
Biomarker Expression (Percent Reactive Cells)
Donor CD73 CD90 CD105 CD146 CD34 CD45 CD14 CD11b Viability Sterility Endotoxin (EU/mL)
1 99.0 99.0 100.0 96.9 1.6 1.7 1.0 0.9 89.0 No Growth < 5.0
2 100.0 100.0 100.0 99.5 0.5 0.6 0.1 0.6 89.0 No Growth < 5.0
3 99.8 99.7 99.8 95.1 2.3 1.2 0.2 1.1 92.0 No Growth < 5.0
5 99.9 99.9 99.9 99.9 2.2 0.9 0.7 0.9 95.0 No Growth < 5.0
7 99.8 99.8 99.8 99.6 2.2 0.8 0.6 0.8 95.0 No Growth < 5.0
10 99.7 99.7 99.8 99.7 0.9 0.9 0.6 0.9 94.0 No Growth < 5.0
11 99.4 99.4 99.7 98.9 3.4 1.2 1.4 1.6 95.0 No Growth < 5.0
14 99.6 99.6 99.7 98.9 5.6 0.5 0.1 0.5 94.0 No Growth < 5.0
Figure 1 Effects of donor age on the quantity of CD34+ cells and total nucleated cells (TNC) in the aspirated marrow. The relationship
between the age of the donor and the quantity of TNCs (Panel A, open squares), percentage of leukocytes expressing CD34 (Panel A, filled
circles) and the total number of CD34+ cells in the marrow aspirate (Panel B) are shown. R stands for correlation coefficient and P stands for P
value both of which were calculated using a regression model.
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than late passage BMSCs [28]. Many studies do not pro-
vide detailed information on the production of the
BMSCs used in their trials, but BMSC products from
one study that successfully treated acute GVHD were
passage 1 through 4 cells [10]. Another recent BMSC
clinical trial suggested that the survival of therapy resis-
tant acute GVHD patients treated with early passage
BMSCs was better than those treated with late passage
cells [29]. It is not certain at which passage BMSCs
change from an early to late passage phenotype, but it is
quite possible that BMSCs produced in large lots and
that have undergone 5 or more passages may have
begun to acquire a late passage phenotype and may be
less effective [25].
There is also considerable evidence of variability in
BMSCs due to donor factors. These factors include
donor age, inherent inter-donor biological variability
and day-to-day intra-donor variability. The use of a
large number of BMSC products produced from only 1
or 2 donors could skew the clinical results of BMSC
therapy due to donor selection. It could be that all of
the BMSC products used for one clinical trial are from
as i n g l ed o n o ra n da l lB M S Cp r o d u c t sf o ra n o t h e r
similar clinical trial are from a second donor, but the
outcomes of the trials differ because of differences due
to donor factors. On the other hand the overall out-
comes of clinical trials that make use of multiple lots of
BMSC products produced from several different donors
are less likely to be effected by variability of individual
donor BMSCs.
While BMSCs have been shown to be effective in a
number of early phase clinical trials, the critical proper-
ties of BMSCs that are responsible for their effectiveness
are not known. BMSCs secrete many cytokines and
growth factors and many of these may be responsible
for the clinical effectiveness of BMSC products. How-
ever, it is possible that the mechanisms of action are
complex and multiple factors may be responsible for
their clinical effectiveness. Furthermore, the factors con-
tributing to clinical effectiveness may vary with disease
type. As a result at this time there are no high quality
biomarkers for assessing BMSC potency. Due to the
lack of good BMSC potency biomarkers we choose to
produce BMSCs using techniques that are very similar
t ot h o s eu s e db yo t h e rg r o u p sw h o s eB M S Cp r o d u c t s
have been shown to be clinically effective; growth in
FBS and the use of low passage number cells. Some
Figure 2 Effect of donor age on the marrow aspirate CFE and the quantity of BMSCs harvested from the primary culture.T h e
relationship between the age of each donor and the CFE of the aspirated marrow (solid circles) and the quantity of BMSCs harvested from the
primary culture (open triangles) is shown in panel A. The effects of donor age and gender on the marrow aspirate CFE is shown in panel B and
on the quantity of BMSCs from the primary harvest is shown in panel C. The relationship between marrow aspirate CFE and the quantity of
BMSCs from the primary harvest is shown in panel D. R stands for correlation coefficient and P for P value. Both were calculated using a
regression model. Differences between males and females were compared using t-tests. * indicates significant differences (p < 0.05)
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Page 9 of 12other production facilities have elected to use media
supplemented with growth factors and cytokines rather
than FBS [30,31]. However, it is not clear if these
changes in BMSC production techniques will influence
their clinical effectiveness.
We found that our cell processing laboratory could
scale up, produce and validate BMSC products, but this
process is relatively expensive. The use of healthy
donors for BMSC production required the development
of a number of new procedures and data collection, sto-
rage and monitoring systems. These procedures and sys-
tems required considerable time and resources to
develop. However, producing BMSCs in our institution
provides several benefits.
Our donor screening and evaluation, marrow collec-
tion and BMSC production process is well defined and
highly controlled. By tightly controlling this process we
expect to maximize consistency among the lots of
BMSC products. This will help minimize variability in
clinical outcomes due to lot-to-lot variability.
The use of BMSC products made within our facility
permits product analysis and clinical correlation with
product characteristics that are critical to the develop-
ment of new biological therapies. We are storing ali-
quots from each BMSC lot that will be used clinically to
evaluate each lot and compare BMSC properties to clin-
ical outcomes. These studies will likely improve the
understanding of the mechanism of action of BMSCs.
Commercial manufacturers of BMSC products often do
not permit the analysis of their BMSC products by the
treating hospital or clinicians. Also, the exact nature of
the commercial formulation is not known and there are
many concerns on the manufacture of commercial pro-
duct that may contribute to the less than optimal
results. At least one of the commercially available pro-
ducts used bone marrow aspirates from a single unre-
lated donor to generate millions and millions of cells
[13]. In such an instance, it is probable that growth fac-
tors were added to BMSC cultures by the company. The
addition of growth factors such as fibroblastic growth
factor, have been known to result in the loss of a subset
of stem cells in bone marrow stromal cells [32]. The
enormous number of population “doublings” in the
strategy used commercially will result in telomere
Figure 3 Factors affecting the quantity of BMSCs from the final harvest. The relationship between the quantity of BMSCs from the final
harvest and the quantity of BMSCs in the primary harvest are shown in Panel A and the relationship between BMSCs in final harvest and donor
age are shown in Panel B. The effects of the quantity of TNC in the marrow aspirate (Panel C), marrow aspirate CFE (Panel D) and percentage of
leukocytes expressing CD34 in the marrow aspirate (Panel E) on the quantity of BMSCs in the final harvest are also shown. R stands for
correlation coefficient and P for P value. Both were calculated using a regression model. *indicates significant differences (p < 0.05)
Sabatino et al. Journal of Translational Medicine 2012, 10:23
http://www.translational-medicine.com/content/10/1/23
Page 10 of 12shortening; cells with longer telomeres were found to be
critical for the success of adoptive transfer of tumor
infiltrating T lymphocytes in patients with metastatic
melanoma [33].
Producing BMSCs at our institution also allows us to
modify our production process if an alternative method
that results in a more effective product is identified at
our institution or at another institution. If we had
elected to use cells produced by a commercial labora-
tory, we would have no control over the production of
the cells.
Conclusions
To our knowledge this is the most comprehensive
description of a GMP program at an academic health
center to assess third party BMSC donors, aspirate mar-
row, produce and store BMSC products for clinical use.
The GMP production and storage of clinical BMSCs
from healthy third party donors is feasible, but is limited
by the high number of donors that did not meet eligibil-
ity criteria and products that did not meet lot release
criteria.
As BMSC therapy matures mechanisms of action will
be defined and potency markers identified and the best
production method described. At that time for many
clinical applications it will likely be best to produce
BMSCs at large commercial facilities. However, in this
early stage of the development of this field, the produc-
tion of BMSCs in academic facilities is beneficial and in
many ways preferred.
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